Inventor · disambiguated record
Mara Gerloni
Also filed as: GERLONI MARA
7 granted patents·4 pending applications·4 citations·filing 2007–2024
79Inventor score
Top patents by PatentIndex Score
11 records- 0191US11986484B217α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumorsCOSMO TECHNOLOGIES LTD·Filed 2022·Granted May 21, 2024·1 cites·3 claims
- 0286US11712443B217α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumorsCOSMO TECHNOLOGIES LTD·Filed 2021·Granted Aug 1, 2023·1 cites·6 claims
- 0385US2024277731A117a-monoesters and 17a,21-diesters of cortexolone for use in the treatment of tumorsCOSMO TECHNOLOGIES LTD·Filed 2024·Application pending·0 cites
- 0482US10993949B217α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumorsCOSMO TECHNOLOGIES LTD·Filed 2020·Granted May 4, 2021·1 cites·2 claims
- 0577US10646497B217α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumorsCOSMO TECHNOLOGIES LTD·Filed 2018·Granted May 12, 2020·1 cites·9 claims
- 0665US2019175618A117alpha-monoesters of cortexolone for use in the treatment of tumorsCOSMO TECHNOLOGIES LTD·Filed 2019·Application pending·0 cites
- 0758US10231980B2Cortexolone 17alpha-benzoate for use in the treatment of tumoursCOSMO TECHNOLOGIES LTD·Filed 2015·Granted Mar 19, 2019·0 cites·14 claims
- 0858US10183030B217α,21-diesters of cortexolone for use in the treatment of tumorsCOSMO TECHNOLOGIES LTD·Filed 2015·Granted Jan 22, 2019·0 cites·5 claims
- 0957US2024408008A1An in-situ gelling enema of rifamycin for treating pouchitis and distal ulcerative colitisCOSMO TECHNOLOGIES LTD·Filed 2022·Application pending·0 cites
- 1052US8691959B2Plasmids with immunological actionGERLONI MARA·Filed 2011·Granted Apr 8, 2014·0 cites·1 claims
- 1152US2010040648A1Plasmids with immunological actionINTERNAT INVEST AND PATENTS SA·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mara Gerloni files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →